# Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

Study · id `cardio:ct-nct03304821` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03304821](<https://clinicaltrials.gov/study/NCT03304821>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03304821

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

## Technical summary

Registry record NCT03304821. Randomized; double masking; primary purpose treatment. Start 2017-12-19 (actual); primary completion 2025-07-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 114 participants (enrolled count; ClinicalTrials.gov record NCT03304821, source copy `cardio:ctgov-nct03304821-2026-08-12`, retrieved 2026-10-31)
- Started: 2017-12-19 (actual) (ClinicalTrials.gov record NCT03304821, source copy `cardio:ctgov-nct03304821-2026-08-12`, retrieved 2026-10-31)
- Primary completion: 2025-07-05 (actual) (ClinicalTrials.gov record NCT03304821, source copy `cardio:ctgov-nct03304821-2026-08-12`, retrieved 2026-10-31)
- Completion: 2025-07-05 (actual) (ClinicalTrials.gov record NCT03304821, source copy `cardio:ctgov-nct03304821-2026-08-12`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03304821, source copy `cardio:ctgov-nct03304821-2026-08-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03304821-2026-08-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- Acronym: GPAD-3
- Condition: Peripheral Artery Disease (PAD)
- Intervention (Drug): GM-CSF
- Intervention (Drug): Placebo
- Lead sponsor: Emory University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: b5e2714f8ff9383605e2a70148e2188d9e5e82fc15f5436d586c7448232fa4f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
